Marina Chiara Garassino to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Marina Chiara Garassino has written about Programmed Cell Death 1 Receptor.
Connection Strength
1.133
-
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 02 01; 25(3):989-999.
Score: 0.597
-
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. Cancer Immunol Res. 2021 03; 9(3):261-264.
Score: 0.176
-
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 05; 130:155-167.
Score: 0.166
-
Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes? Ann Oncol. 2021 06; 32(6):814-816.
Score: 0.044
-
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clin Cancer Res. 2021 01 15; 27(2):492-503.
Score: 0.043
-
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019 Aug; 15(23):2743-2757.
Score: 0.040
-
Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Target Oncol. 2018 12; 13(6):795-800.
Score: 0.038
-
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
Score: 0.030